Essais liés9clinical trials
VilleWarsawlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05639114

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Remibrutinib (Blinded) SEP Phase 3 NCT07225504 REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis RECRUITING
VHB937 Sclérose latérale amyotrophique Phase 2 NCT06643481 ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) ACTIVE_NOT_RECRUITING
Ianalumab Lupus Phase 3 NCT05639114 Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) ACTIVE_NOT_RECRUITING
Remibrutinib (Blinded) Myasthénie Phase 3 NCT06744920 RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis RECRUITING
Iptacopan Myasthénie Phase 3 NCT06517758 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. ACTIVE_NOT_RECRUITING
Nilotinib followed by treatment-free Cancer Phase 2 NCT01784068 ENESTfreedom — Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients COMPLETED
Ianalumab Lupus Phase 3 NCT06133972 Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). RECRUITING
RAD001 Épilepsie Phase 3 NCT01713946 A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures COMPLETED
Fingolimod SEP À vérifier NCT01285479 The Gilenya Pregnancy Registry COMPLETED